Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • ADVANCED ONCOTHER. LS-,25 News

    0,0215 € 0,00% +0,00 €
    29.06.23 21:50:01 Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2AL9X
    ISIN: GB00BD6SX109
    US-Symbol: AONCF
    Typ: Aktie

    ADVANCED ONCOTHER. LS-,25 News

    27.01.23 - DGAP
    Hardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
    Hardman & Co Research Hardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date 27-Jan-2023 / 16:53 ...
    17.01.23 - DGAP
    Hardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
    Hardman & Co Research Hardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV 17-Jan-2023 / 15:10 GMT/BST Hardman & Co ...
    29.09.22 - DGAP
    Hardman & Co Research on Advanced Oncotherapy: Major milestone achieved
    Hardman & Co Research Hardman & Co Research on Advanced Oncotherapy: Major milestone achieved 29-Sep-2022 / 07:15 GMT/BST Hardman & Co Research on Advanced ...
    14.03.22 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update 14-March-2022 / 07:15 GMT/BST Hardman & Co Research on ...
    15.11.21 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): On the home straight
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): On the home straight 15-Nov-2021 / 08:30 GMT/BST Hardman & Co Research: On the home ...
    12.08.21 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO) Funded to completion
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO) Funded to completion 12-Aug-2021 / 13:50 GMT/BST Hardman & Co Research: Funded to ...
    15.12.20 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): Leveraging the modularity of LIGHT
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Leveraging the modularity of LIGHT 15-Dec-2020 / 07:15 GMT/BST Hardman & Co Research ...
    23.10.20 - DGAP
    Hardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT
    Hardman & Co Research Hardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy: Progress towards commissioning of first LIGHT 23-Oct-2020 / 14:25 ...
    07.10.20 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): Progress towards commissioning of first LIGHT
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Progress towards commissioning of first LIGHT 07-Oct-2020 / 10:50 GMT/BST Hardman & Co ...
    02.07.20 - DGAP
    Hardman & Co Research : Advanced Oncotherapy (AVO): End-goal fast approaching
    Hardman & Co Research Hardman & Co Research : Advanced Oncotherapy (AVO): End-goal fast approaching 02-Jul-2020 / 07:15 GMT/BST Hardman & Co Research: Funded ...
    26.02.20 - DGAP
    Hardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
    Hardman & Co Research Hardman & Co Research: Q&A with Dr Martin Hall on Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum 26-Feb-2020 / 15:40 ...
    17.02.20 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum 17-Feb-2020 / 11:45 GMT/BST Hardman & Co Res ...
    04.12.19 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): Proving the accuracy and superiority of minibeams
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Proving the accuracy and superiority of minibeams 04-Dec-2019 / 07:15 GMT/BST Hardman & ...
    11.11.19 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): FLASH benefits from new US reimbursement
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): FLASH benefits from new US reimbursement 11-Nov-2019 / 09:11 GMT/BST Hardman & Co ...
    08.08.19 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal 08-Aug-2019 / 10:45 GMT/BST
    16.05.19 - DGAP
    Advanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
    goetzpartners securities Limited Advanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth 16-May-2019 / 14:23 GMT/BST
    16.04.19 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation 16-Apr-2019 / 10:26 GMT/BST
    16.04.19 - DGAP
    Advanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
    goetzpartners securities Limited Advanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT 16-Apr-2019 / 09:11 GMT/BST
    21.01.19 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval 21-Jan-2019 / 11:15 GMT/BST
    16.10.18 - DGAP
    Hardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
    Hardman & Co Research Hardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated 16-Oct-2018 / 16:30 GMT/BST

    Newssuche

    Videos

    26.04.24 -5,94%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »